BRCA1 and breast cancer: Within the breast cancer cell lines we screened lacking BRCA1/2 mutations, the PARPi sensitivity signature predicted to five to be sensitive (HCC-1806, CAMA1, MCF7, MDA-MB-231, and BT-549).